Trial Profile
A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Recifercept (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 16 May 2023 Status changed from active, no longer recruiting to discontinued.
- 27 Jan 2023 Planned End Date changed from 4 Jan 2024 to 31 Mar 2023.
- 27 Jan 2023 Status changed from recruiting to active, no longer recruiting.